Further observations on the use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome.
The effects of 5-hydroxytryptophan (5-HTP), a serotonin precursor, and carbidopa, a peripheral aromatic amino acid decarboxylase inhibitor, were studied in a boy with the Lesch-Nyhan syndrome. No effects on the self-mutilating behaviors of this disorder were noted. However, sleep patterns were normalized, with a reduction in the proportionate amounts of wakefulness and an augmentation of active sleep. A sharp reduction in waking behavioral dyskinesias was also correlated to increased drug dosage.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D002230:Carbidopa / Q000627:therapeutic use*; D002648:Child; D004359:Drug Therapy, Combination; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007926:Lesch-Nyhan Syndrome / Q000188:drug therapy*; D008297:Male; D009069:Movement Disorders / Q000188:drug therapy; D012652:Self Mutilation / Q000188:drug therapy; D012890:Sleep / Q000187:drug effects; D014851:Wakefulness / Q000187:drug effects
D006834:Hydrazines; D006916:5-Hydroxytryptophan; D002230:Carbidopa